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ABSTRACT 
Objective: Studies have shown that a new combination therapy with artemisinin derivatives and curcumin is unique, with potential advantages 
over known Artemisinin Combination Therapy (ACT). The problems of poor solubility, stability and bioavailability of curcumin can be overcome by 
preparing curcumin metal complex. In present study curcumin-Zn complex was prepared and evaluated for antimalarial activity in combination 
with artemether. 
Methods: Curcumin Zn complex was prepared using zinc sulfate. The mice survival and % parasitemia were studied in Plasmodium berghei (P. 
berghei) infected albino mice treated with curcumin, curcumin-Zn complex and combination of curcumin-Zn with artemether. 
Results: The mean survival time in mice infected with P. berghei was compared after treatment with curcumin, curcumin-Zn, artemether and 
combination of curcumin-Zn-artemether. Oral administration of curcumin-Zn-artemether prolonged the survival of P. berghei infected mice. All the 
mice were treated with Curcumin-Zn (5 mg/day) artemether (1000 µg) survived for more than 40 d and recovered with no detectable parasitemia. 
Administration of curcumin-Zn artemether combination reduced the parasitemia in mice more effectively compared to that in mice treated with a 
single drug.  
Conclusion: In vivo antimalarial activity of curcumin-Zn complex was found superior to curcumin. A single dose of 1000 µg of artemether in 
combination with curcumin-Zn gives complete protection in P. berghei infected mice. Such suppressive action was superior to that of administration 
of the single drug at the same dose. This may reduce the chances of drug resistance. 
Keywords: Curcumin-Zn complex, Artemether, Mice survival, % parasitemia. 
 
INTRODUCTION 
Resistance to first line drugs to treat malaria is the prime problem in 
controlling it. Parasitic resistance to chloroquine and then to others was 
first noticed in the 1979 and has since spreading all over the world. 
Chloroquine-resistance is associated with reduced sensitivity to other 
drugs such as quinine and amodiaquine. Immediate measures are 
needed to replace antimalarial drugs which are rapidly becoming 
ineffective with newer, cheaper and effective antimalarial [1].  
Combination therapies preferably using “novel” antimalarial drugs 
are the way forward for improving therapeutic efficacy and delaying 
development of resistance in antimalarial treatment. Artemisinin 
(qinghaosu), artesunate, artemether and dihydroartemisinin have all 
been used in combination with other antimalarial drugs for the 
treatment of malaria. Artemisinin derivatives are eliminated rapidly 
and have a short half-life. When given in combination with a longer 
half-life “partner” antimalarial drug allows a reduction in the 
duration of treatment, while at the same time enhancing efficacy and 
reducing the likelihood of resistance development [2].  
The natural product curcumin is a polyphenolic compound extracted 
from the rhizome of Curcuma longa L. In India, it is commonly used as 
a spice to add color and flavor to the food. In Ayurveda, use of 
curcumin is well documented for the treatment of various ailments [3].  
Studies have shown that a new combination therapy with 
artemether (ARM) and curcumin is unique, with potential 
advantages over the known ACTs. Both drugs have short half-lives 
and no resistance is known to curcumin. Curcumin, in addition to 
having a direct killing effect as an antimalarial, is also able to 
activate the immune system against P. berghei [4, 5]. 
An important issue with curcumin is its poor bioavailability, less 
stability, rapid metabolism and short half-life [6]. Several attempts 
are under way to improve bioavailability through the use of 
preparations such as liposomes, phospholipid complexes, 
nanoparticles or microparticles [7, 8]. Complexing curcumin with 
transition metals is one of the useful ways to overcome the problem 
related to solubility, bioavailability and stability [9]. In present study 
curcumin-Zn complex was prepared and evaluated for antimalarial 
activity as single drug therapy and in combination with artemether. 
MATERIALS AND METHODS 
Curcumin was purchased from Phytopharma actives Pvt. Ltd., 
Mumbai. Giemsa stain (Himedia), tween 60, zinc sulfate and glycerol 
(Research lab) were purchased from local markets. 
Animals  
Inbred albino rats were obtained from the animal house of Pravara 
Medical College, Pravaranagar. The research was conducted in 
accordance with standard institutional guidance given by the 
Institutional Animal Ethics Committee (IAEC). The Labs used for the 
purpose was approved by Committee for the purpose of control and 
supervision of experiments on animals, Ministry of social justice and 
empowerment, Govt. Of India (Registration No.-448/01/c/CPCSEA). 
Preparation of curcumin-Zn complex  
Zinc sulfate (ZnSO4·7H2O) was mechanically mixed in a mortar with 
curcumin (Zn2+: Curcumin 1/1 mole) until homogenous powder 
mixture was obtained. Then, glycerol/water (1: 1 v/v) solution was 
added to mixture, followed by mechanical shaking at 25 °C until 
pasty combination was obtained. Pasty product was dried at 50 °C 
and free glycerol was eliminated by washing with distilled water. A 
dark-colored powder complex of curcumin-Zn was obtained [10]. 
Characterization of curcumin and curcumin-Zn complex [11, 12] 
Fourier transform infrared spectroscopy (FTIR) analysis 
FTIR spectroscopy of curcumin and curcumin-Zn complex was 
performed on FTIR (Jasco FT/IR-4100) spectrophotometer. About 5 
mg of sample was mixed with 100 mg of Potassium bromide (KBr) 
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and compressed to form pellets. The spectra of sample was scanned 
from a wave number range of 650 to 4000 cm-1. 
UV spectroscopy 
Solution of curcumin and its metal complex were prepared in 
Dimethyl Sulphoxide (DMSO) and scanned on UV spectrophotometer 
in the range 350 to 600 nm to find λ max. UV spectrophotometric 
analysis was done to confirm the formation of curcumin-Zn complex. 
Antimalarial activity [13, 14] 
Mice survival study 
Male albino mice were used for the study. Tap water and mouse feed 
was provided ad libitum. P. berghei (ANKA strain) erythrocytic 
stages were maintained by serial passing of infected blood in male 
albino mice. Animals were divided into nine groups based on the 
treatment. Mice were injected intraperitonally (i. p.) with 107 P. 
berghei infected mouse erythrocytes. Control group (group no 1) 
was only given 5% tween 60. Mice in group 2 and 3 received an oral 
suspension of curcumin-Zn and curcumin respectively in corn oil at 
a dose equivalent to 5 mg of curcumin on d 1, 2 and 3. Animals in 
group 4, 5 and 6 received by oral route a combination of curcumin-
Zn (equivalent to 5 mg curcumin on d 1, 2 and 3) and i. p. injection of 
artemether at single dose of 0.5, 1 or 1.5 mg, respectively (on d 1). 
While artemether was injected intraperitonally as a suspension in 
5% tween 60 to animals in group 7, 8 and 9 with a dose of 0.5, 1 or 
1.5 mg (on d 1) respectively. The survival time (over 40 d post 
treatment) of mice infected with the erythrocytic stages of P. berghei 
was compared in different groups. 
Determination of mean survival time 
Mortality was monitored daily and the number of d from the time 
of incoculation of the parasite up to death was recorded for each 
mouse in the treatment and control groups throughout the follow 
up period. The mean survival time (MST) for each group was 
calculated as:  
 
Percent mean parasitemia in mice [15] 
Parasitemia was monitored by light microscopy (oil immersion, 
1000× magnification) by examining thin smears of blood from the 
tail veins of the mice.  
Blood films are made by applying 4.5 microlitres of blood to 
microscope slides as soon as the specimen is received. Thin blood 
films were fixed in methanol and stained with Giemsa stain 
immediately after slide production. The parasitemia level was 
determined by counting, in random fields of the microscope, the 
number of parasitized RBCs. The percent of infected RBCs were 
determined by enumerating the number of infected RBCs in relation 
to the number of uninfected RBCs. A minimum of 500 RBCs was 
counted per sample.  
 
Inoculation of P. berghei to mice was done on d 0, while percent 
mean parasitemia was measured on d 1, 2, 3 and 4. The blood 
samples were collected after 4 hours of receiving treatment as per 
specified above and at the same time on the next days.  
% Suppression of parasitemia 
The percentage suppression of parasitemia was calculated for each 
test concentration by comparing the parasitaemia in infected 
controls with those received different concentrations of the 
treatments. Percent parasitemia suppression were calculated as 
 
Where, A is mean % parasitemia in the control group and B is % 
parasitemia in the treatment group. 
Statistical analysis 
All data were expressed as mean±SD. The statistical analysis of all 
the observations was carried out using one-way ANOVA followed by 
a multiple comparison test of Tukey, where necessary. P<0.05 was 
considered as significant compared with the control group and all 
data were analysed at a 95% confidence interval. 
RESULTS AND DISCUSSION 
Curcumin and curcumin-Zn complex in powdered form were 
scanned between wave number 4000 to 650 cm-1. The resultant 
spectrum obtained has shown in fig. 1 and 2. 
The major peaks of the spectrum were then interpreted so as to 
determine the respective functional groups present. The results are 
shown in table 1. 
  
 
Fig. 1: FTIR spectrum of curcumin 
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Fig. 2: FTIR spectra of curcumin-Zn complex 
 
Table 1: Interpretation of the FTIR spectrum 
Reported  
(Cm-1) 
Observed for curcumin (cm-1) Observed for curcumin-Zn(cm-1) Functional group Determination 
3510.2 3502 - Phenolic OH (Streching) 
1627.8 1629 1626 Ketone C=O (Streching) 
1596 1603 1588 Aromatic C=C 
1276 1276 1269 C-O 
 
The 1629 and 1603 cm-1 bands correspond to the mixtures of 
stretching vibrations of (C=C) and (C=O) in curcumin were red 
shifted to 1625 and 1588 cm-1 in the curcumin-Zn complex 
respectively. 
UV Spectrophotometric determination 
UV spectra of curcumin and its metal complex were developed by 
dissolving it in DMSO.  
 
 
Fig. 3: UV spectral data of curcumin and curcumin-Zn complex 
 
Their spectra was deconvoluted with an absorption band at 435 nm 
for curcumin, at 432 nm for curcumin-Zn complex (fig. 3). From 
FTIR and UV analysis of curcumin and curcumin-Zn, it was 
confirmed that curcumin-Zn complex was successfully prepared. 
Antimalarial study 
Mice survival test 
The mean survival time of mice infected with the erythrocytic stages of 
P. berghei was compared in different groups as shown in table 2. All 
mice in the control group died in 7 d post exposure to infection. 
Animals in group 2 and 3 have shown 100% mortality by the 16th and 
10th
All animals in group 4 and 5 have survived by the 40
 d respectively. It was observed that animals in group 2 treated 
with curcumin-Zn have survived for longer time than animals treated 
with curcumin (group 3) suggesting the superior antimalarial action of 
curcumin-Zn than curcumin. But it failed to give complete protection 
against P. berghei infection in mice. 
th
Percent mean parasitemia in mice 
 d with 100 % 
protection against P. berghei infection (fig. 4). Comparing mean 
survival time and % protection between same dose (artemether) 
groups viz. 6 and 9, 5 and 8, 4 and 7, it was observed that the 
combination of artemether and curcumin-Zn has offered more 
protection than artemether (single drug) administration. The 
combination of curcumin-Zn artemether prolonged the survival time 
as compared to administration of single drug at the same dose as all 
the animals in group 4 and 5 have survived by the d 40. 
There was marked variation in percent mean parasitemia in mice 
receiving control, curcumin, curcumin-Zn, combination of curcumin 
Zn-artemether and artemether for the first 4 d post infection as 
shown in fig. 5. The percent mean parasitemia in control mice was 
drastically increased showing that more RBCs are parasitized with 
time.  
The values for percent mean parasitemia on 4th d and % suppression 
of parasitemia in mice receiving various treatments are reported in 
table 3. Animals in group 2 and 3 showed an increase in percent 
mean parasitemia to 39.65 and 54.12 respectively on d 4. Increase in 
percent mean parasitemia in animals of group 2 was less than 
animals of group 3 thus supporting the claim of superior 
antimalarial action of curcumin-Zn than curcumin.  
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Animals in group 4 and 5 showed maximum % parasitemia 
suppression, respectively 90.86 and 88.35 on d 4. It was observed 
that combination drug treatment has led to suppression of 
parasitemia more effectively than single drug administration. The 
animals in group 4 and 5 recovered with no detectable parasitemia 
after 40 d in the mice survival study. 
 
Table 2: Mean survival time in P. berghei infected mice 
Gr No. Treatment Dose Mean survival time (days) 
1 Control  6.1 
2 Curcumin Zn complex 3 D 5 mg/d 10.2 
3 Curcumin 3 d 5 mg/d 7.6 
4 Curcumin-Zn+ 
artemether combination 
3 D 5 mg/d 




3 D 5 mg/d 




3 D 5 mg/d 




Artemther 1.5 mg i. p. 33.4
8 
* 
1.0 mg i. p. 24.6
9 
* 
0.5 mg i. p. 17.2* 
*P<0.05, **P<0.001 compared to control 
 
 
Fig. 4: Percent mean protection in mice receiving different 
treatments over time (40 d post treatment), * (n=5) 
 
Fig. 5: Percent mean parasitemia in mice receiving different 
treatments
 
Table 3: Percent suppresion of parasitemia and % mean parasitemia of mice 
Group 
no. 
Treatment Dose % Suppression of parasitemia on the following d 
after treatment 
% mean parasitemia 
on 4th day 
1 2 3 4  
1 Control  - - - - 56.51±5.2 
2 Curcumin Zn complex  3Days,5 
mg/d 












+1.5 mg i. p 





+1.0 mg i. p 





+0.5 mg i. p 
12.59 58.02 68.23 68.21 17.96±2.8
7 
** 
Artemther 1.5 mg i. p 14.53 56.23 75.79 83.98 9.05±1.5
8 
** 
1.0 mg i. p 5.03 58.35 72.48 76.78 13.12±2.2
9 
** 
0.5 mg i. p 6.97 51.06 54.98 55.29 25.26±2.2 
Data are expressed as mean±SD (n = 5); *P<0.05, **P<0.001 compared to control 
 
CONCLUSION 
Curcumin a natural polyphenolic compound possess antimalarial 
activity, but its use is restricted because of poor solubility, stability 
and bioavailability. In both mice survival and % parasitemia 
inhibition study, it was found that curcumin-Zn complex has 
superior antimalarial activity than curcumin. Administration of the 
combination of curcumin-Zn and artemether has increased survival 
rates to 100% and reduced the parasitemia more effectively in mice. 
Such suppressive action was superior to that of administration of 
the single drug at the same dose. The antimalarial potential of 
curcumin can be re-explored by using curcumin metallo complex 
with improved solubility, stability and bioavailability. 
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